Search
STIFEL 2026: Oruka's IL-23p19 is showing strong efficacy in p2 psoriasis studies compared to existing products and might be dosed as little as once or twice a year - a key update will read next month
CEO Lawrence Klein describes the data that has been seen so far (clearance in the 60% range at 16 weeks) and previews with upcoming 52 week data that will be coming in December. Plus, how the company is thinking about phase 3 design, and other assets in the pipeline. Coverage brought to you by
19 minutes ago
Spun out of Paragon, Oruka Therapeutics raised $275M today as part of a reverse merger to tackle skin conditions in the I&I space
CEO Lawrence Klein describes advances in antibody engineering Oruka is leveraing to make improved IL-23 and IL-17 inhibitors.
Apr 3, 2024
.png){kind=logo}
